Antibody–drug conjugates to treat lung cancer
Antibody–drug conjugates are an emerging therapeutic option in lung cancer.
Three antibody–drug conjugates have received FDA approval so far including trastuzumab deruxtecan, telisotuzumab vedotin, and datopotamab deruxtecan.
Several promising antibody–drug conjugates are currently being evaluated in Phase 2 and 3 clinical trials.
https://www.cell.com/trends/cancer/fulltext/S2405-8033(26)00213-X
https://sciencemission.com/antibody%E2%80%93drug-conjugates-28524
